Chronic Systemic Therapy With Low-dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx Mice
Open Access
- 1 February 2011
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (2), 345-354
- https://doi.org/10.1038/mt.2010.261
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse ModelMolecular Therapy, 2010
- Dosing Regimen Has a Significant Impact on the Efficiency of Morpholino Oligomer-Induced Exon Skipping in mdx MiceHuman Gene Therapy, 2009
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal musclesProceedings of the National Academy of Sciences of the United States of America, 2004
- Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscleHuman Molecular Genetics, 2003
- Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouseNature Medicine, 2003
- Somatic reversion/suppression of the mouse mdx phenotype in vivoJournal of the Neurological Sciences, 1990
- Very mild muscular dystrophy associated with the deletion of 46% of dystrophinNature, 1990
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988
- X chromosome-linked muscular dystrophy (mdx) in the mouse.Proceedings of the National Academy of Sciences of the United States of America, 1984